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Acquired therapy resistanceSignal transducer and activator of transcription (STAT) 1 is part of the Janus kinase (JAK)/STAT signalling
cascade and is best known for its essential role in mediating responses to all types of interferons (IFN).
STAT1 regulates a variety of cellular processes, such as antimicrobial activities, cell proliferation and cell
death. It exerts important immune modulatory activities both in the innate and the adaptive arm of the
immune system. Based on studies in mice and data from human patients, STAT1 is generally considered a
tumour suppressor but there is growing evidence that it can also act as a tumour promoter. This review
aims at contrasting the two faces of STAT1 in tumourigenesis and providing an overview on the current
knowledge of the underlying mechanisms or pathways.
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STAT1 is one of the seven mammalian members of the STAT
family [1]. STAT1 transduces signals from cytoplasmic domains
of transmembrane receptors into the nucleus where it regulates
gene expression. Thereby it modulates diverse cellular processes,
such as proliferation, differentiation and cell death. STAT1 function
is central in the innate and adaptive arm of immunity and protects
from pathogen infections [2]. It transduces activities of different
cytokines, including type I-III interferons (IFNs), interleukin (IL)-
21, IL-27 and IL-35 [3–5].
STAT1 activation is transient and tightly regulated. Phosphory-
lation on tyrosine 701 (Y701) of STAT1 (pSTAT1) by Janus kinases
(JAKs) leads to its activation and nuclear translocation. Serine
727 (S727) phosphorylation is required for full transcriptional acti-
vation upon IFN stimulation and in response to cellular stress [6].
Activated STAT1 regulates transcription of protein-encoding genes,
including Stat1 itself. It also drives the expression of microRNAs
(miRNAs), which regulate gene expression at the mRNA or transla-
tional level [7]. Alternative splicing generates two STAT1 isoforms,
the full length STAT1a and the truncated STAT1b. The latter lacks
part of the C-terminal transactivation domain, including the S727
phosphorylation site, and was considered to be transcriptionally
inactive. STAT1 isoform specific knock-in mice revealed that
STAT1b is capable to drive transcription, albeit delayed and to
reduced levels as compared to STAT1a [8]. Due to the lack of
appropriate in vivo models and analytical tools, STAT1 isoform
specificity in carcinogenesis and immunity has not yet been thor-
oughly addressed. Transcriptional activity has also been assigned
to unphosphorylated STAT1 (U-STAT1) [9–11]. U-STAT1 maintains
heterochromatin stability in Drosophila [12] and in mammalian
cells [13–15]. STAT1 activation is inhibited at different levels, e.g.
feedback inhibition of JAKs by suppressor of cytokine signalling
(SOCS) proteins, dephosphorylation of STAT1 by phosphatases
(e.g., the SH2 domain-containing protein-tyrosine phosphatase
SHP2), nuclear export of STAT1 and inhibition of DNA binding by
protein inhibitors of activated STATs (PIAS) [16–20].
In general, STAT1 is considered a tumour suppressor, although
there is increasing evidence for tumour promoting functions of
STAT1. Mechanistic insights in vivo grossly stem from Stat1-
deficient mice and various murine cancer models. Patients with
inborn STAT1 mutations that lead to loss- or gain-of-function suf-
fer from severe diseases related to innate immunity and autoin-
flammation [3,21,22]. Human STAT1 mutations have therefore
been rarely studied in the context of cancer. However, a plethora
of studies describe a correlation of altered STAT1 availability
and/or activation states in human tumour samples with disease
outcome. In this review we summarise the current knowledge on
the tumour suppressive and promoting functions of STAT1. The
focus is on correlations with the STAT1 status in solid tumours,
mechanistic aspects and studies in Stat1-deficient (Stat1-/-) mice.2. Tumour suppressive functions of STAT1
Tumour suppressor properties of STAT1 are deduced from the
findings that STAT1 availability and/or activation are reduced or
not detectable in transformed cells and during progression of var-
ious tumours in humans. A correlation of STAT1 expression with
good prognosis has been shown in several types of cancers, includ-
ing colo(rectal) cancer [23–26], hepatocellular carcinoma [27], eso-
phageal cancer [28], pancreatic cancer [29], soft tissue sarcoma
[30] and metastatic melanomas [31]. The prognostic power of
STAT1 in breast cancer appears to be more complex, as correlations
with good and bad prognosis have been reported for both STAT1
expression levels and pSTAT1. Tumour suppressive functions ofPlease cite this article in press as: K. Meissl et al., The good and the bad face
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levels, pSTAT1 and its cell type specificity was reported as an inde-
pendent marker for good prognosis in breast cancer tissue [32,33],
although one study did not find a correlation of STAT1 levels and
disease outcome [34]. However it was also noted that high levels
of Stat1 mRNA, in contrast to pSTAT1, are linked to poor disease
outcome (see chapter 3) [33]. Support for a breast cancer suppres-
sive role of STAT1 was furthermore provided by the finding that
STAT1 expression is reduced in tumour epithelia compared to nor-
mal breast tissue [35] and by pathway analysis of genes with
altered methylation patterns in breast cancer patients [36].
Compelling evidence for suppressive functions of STAT1 in
mammary tumourigenesis was provided by four studies in mice
with different experimental models. Concomitant deletion of Stat1
and expression of the ErbB2/neu oncogene in mammary epithelial
cells, results in a more rapid development of mammary tumours
[37,38]. An increase of spontaneous mammary tumour formation
in multiparous Stat1-/- mice was shown in two studies, although
results differed with respect to tumour frequencies, the frequency
of arising estrogen receptor positive (ER+) tumours and whether or
not virgin mice developed tumours [35,39]. These data have just
recently been comprehensively reviewed and collectively establish
that STAT1 acts as tumour suppressor in both the tumour cells
themselves and in the tumour environment in mice [40,41].
The tumour suppressive functions of STAT1 in other tumour
types have already been demonstrated in earlier studies. Stat1-/-
mice developed methylcholantrene (MCA)-induced tumours with
higher frequency and shorter latency than wild-type mice. Absence
of STAT1 also decreased latency of spontaneously arising tumours
in the absence of the tumour suppressor p53 and, interestingly,
also broadened the tumour spectrum. Parallel analysis of mice
deficient for IFNc (Ifnc-/-) and extensive tumour transplant exper-
iments established that the main function of STAT1 in the MCA-
induced tumour model lies in mediating IFNc-dependent tumour
immune surveillance [42].
Mechanistically, tumour suppression by STAT1 occurs at multi-
ple levels: tumour cell-intrinsic growth control (Fig. 1A) and cross-
talk with other cells to modulate cancer immunoediting and sup-
press angiogenesis (Fig. 1B).
2.1. Tumour cell growth inhibition and cell death
The central role of STAT1 in conveying the anti-proliferative
effects of all types of IFNs is well-established [43–46]. The effects
of STAT1 range from cell cycle inhibition and sentitization to apop-
totic stimuli to the induction of different forms of cell death.
Mechanistically, STAT1 transcriptionally regulates the expres-
sion of cell cycle regulators, pro-apoptotic proteins and death-
receptors and their ligands. The cyclin-dependent kinase (CDK)
inhibitors p21WAF1 and p27KIP1 are induced in an IFN/STAT1 depen-
dent manner in different cell types [47–49]. STAT1-dependent up-
regulation of p27KIP1 was also reported in oncogenic RAS-
transformed mouse embryonic fibroblasts (MEFs) in the absence
of IFN stimulation [50]. Cell cycle inhibition through downregula-
tion of cyclin A, E and CDK2, 4, without up-regulation of p21WAF1
and p27KIP1, was observed in melanoma cell lines [51]. STAT1 can
also induce cell cylce arrest in response to IFNc through interaction
with cyclins D1, D2, D3 and CDK4 in fibrosarcoma cells. STAT1
mediates proteasomal degradation of cyclin D1 by an unknown
mechanism that requires the presence of S727 STAT1. Cell cycle
arrest correlated with reduced phosphorylation of retinoblastoma
protein (Rb), reduced levels of cyclin E and enhanced expression
of p21WAF1 and p27KIP1 [52]. Reduced cyclin E levels, accompanied
by an increase in p53 and enhanced apoptosis, were also found in
hepatocellular carcinoma cell lines upon overexpression of STAT1
[27]. Moreover, STAT1 transcriptionally represses c-myc, a tran-s of STAT1 in solid tumours, Cytokine (2015), http://dx.doi.org/10.1016/j.
Fig. 1. Tumour suppressive functions of STAT1. (A)Molecular mechanisms of cell cycle inhibition and cell death induction by STAT1. In both processes STAT1 acts through
transcriptional regulation and direct protein–protein interactions. Blue lines indicate STAT1 regulated steps. (B) Tumour suppressive activities of STAT1 with respect to
different cellular processes and cross-talk between distinct cell types. STAT1 regulates angiogenesis and cancer immunoediting in a tumour cell-intrinsic and -extrinsic
manner. It inhibits angiogenesis by inducing anti-angiogenic and blocking the production of pro-angiogenic factors in tumour and endothelial cells. By inducing cell cycle
arrest and cell death STAT1 directly inhibits tumour growth. Up-regulation of MHC class I (MHC-I) by STAT1 leads to an efficient recognition and elimination of tumour cells
by cytotoxic T lymphocytes (CTLs). Tumour cell-extrinsic STAT1 promotes anti-tumour immune response by rendering innate and adaptive immune cells fully functional.
Blue lines indicate STAT1 regulated steps.
K. Meissl et al. / Cytokine xxx (2015) xxx–xxx 3scription factor that stimulates cell cycle progression [53,54]. A
more recent study implicated transcriptional up-regulation of the
miRNA-29 family by STAT1 and a consequent down-regulation of
CDK6 in the anti-proliferative activity of IFNc [55].
STAT1 also induces the transcription of Bcl-2 family members,
which sense cellular stress and act on mitochondrial integrity.
Members of the Bcl-2 family either act pro- (e.g. Bax, Bak, Bad)
or anti-apoptotic (e.g. Bcl-2, Bcl-xL) [56]. STAT1 acts on both: it
up-regulates Bak [57] and inhibits the transcription of Bcl-2 and
Bcl-xL [58,59]. STAT1 also induces the expression of different cas-
pases. IFNc/STAT1-induced expression of caspase 1 was seen in
different human cancer cell lines [60,61] and murine epithelial car-
cinoma cells, in which pSTAT1 led to tumour regression [62]. IFNa
increases caspase 8 levels and sensitizes hepatoma cells to tumour
necrosis factor (TNF)-related apoptosis inducer ligand (TRAIL)-
induced apoptosis [63]. Interestingly, STAT1 is required for consti-Please cite this article in press as: K. Meissl et al., The good and the bad face
cyto.2015.11.011tutive expression of caspase 1, 2 and 3, but not caspase 6 and 7 in
human fibrosarcoma cells [64].
IFNc/STAT1 enhances the expression of the death receptor FAS
(also known as tumour necrosis factor receptor superfamily mem-
ber 6) and its ligand FASL in hepatoma and colon adenocarcinoma
cells [65,66] and of TRAIL and its receptor death receptor 5 (DR5) in
myeloma and other cancer cell lines [65,67,68]. Similarly, IFNb
enhances the expression of TRAIL through STAT1 in colorectal can-
cer and fibrosarcoma cell lines [69,70]. IFNa activated STAT1 and
interferon regulatory factor 1 (IRF1) directly induce the expression
of TRAIL in human bladder cancer cells [71] and IFNa increases the
expression of TRAIL and its receptors in lymphoma cells [72].
Accordingly, IFN-activated STAT1 sensitizes tumour cells to various
apoptotic stimuli, including death receptor signals (TNF, FAS,
TRAIL) [63,73,74] and DNA-damaging agents [57,75,76]. These
findings translate into therapy, as combined treatment of IFNas of STAT1 in solid tumours, Cytokine (2015), http://dx.doi.org/10.1016/j.
4 K. Meissl et al. / Cytokine xxx (2015) xxx–xxxand 5-fluorouracil was beneficial in patients with hepatocellular
carcinoma [77] and the synergy of IFNc and TNFa with the onco-
gene inhibitor vemurafenib led to increased growth arrest and cell
death in melanoma cells in mouse models [78].
There is also evidence that STAT1 modulates cell death by direct
protein–protein interaction. Upon DNA damage, STAT1 interacts
with the tumour suppressor p53 in human fibrosarcoma and B cell
lines and in mouse fibroblasts [79,80]. p53 is a transcription factor
that, amongst others, induces cell cycle arrest and cell death upon
different stress stimuli and is frequently mutated and functionally
inactive in human tumours [81,82]. STAT1 facilitates the transcrip-
tional activity of p53 and inhibits the expression of the p53 inhibi-
tor E3 ubiquitin-protein ligase MDM2, thereby enhancing
apoptosis induced by doxorubicin and cisplatin [80]. The ability
to interact with p53 is likely specific for the STAT1a isoform, as
STAT1a, but not STAT1b, overexpression in a Stat1-deficient B cell
line led to an increase in nuclear translocation and transcriptional
activity of p53 in response to fludarabine [83]. Similarly, overex-
pression of STAT1b in a transformed lymphoblastoid cell line that
expresses endogenous STAT1 isoforms prevents nuclear localisa-
tion of p53 and reduced fludarabine-induced cell cycle arrest [79].
Interaction of STAT1 with TNFR1-associated death domain pro-
tein (TRADD), an adaptor protein of the protein complex associated
with the TNF receptor, promotes TNFa induced apoptosis. By inter-
acting with TRADD, STAT1 competes with receptor-interacting
protein (RIP) and TNFR-associated factor 2 (TRAF2) and inhibits
TNFa-induced NFjB activation and the expression of pro-survival
genes, but does not affect apoptotic signalling mediated by the
interaction of TRADD with Fas-associated death domain protein
(FADD) [84].
Recent evidence suggests that IFNc induces non-apoptotic cell
death through induction of the autophagosome. Autophagy is a
lysosomal-dependent degradation process involved in metabolic
regulation and intracellular recycling [85,86]. In human hepatocel-
lular carcinoma cell lines and in primary hepatic carcinoma cells,
IFNc induced autophagosome formation and its inhibition reduced
IFNc-induced cell death [87]. Autophagy has also been implicated
in the therapeutic activity of toll-like receptor (TLR) 4 and 9 agonist
complexes in a mouse model of metastatic melanomas. TLR4 and
TLR9 agonist treatment of mice induced autophagy-associated
death of melanoma cells in an IFNc-dependent manner. Moreover,
pretreatment of mice with IFNc enhanced autophagy in tumour
cells and reduced the number of metastatic nodules [88]. However,
the involvement of STAT1 in these processes remains to be
evaluated.
2.2. Cancer immunoediting
Cancer immunoediting describes the interaction between trans-
formed cells, tumour cells and the immune system and is an
important tumour suppressive mechanism. It includes elimination
of transformed cells and sculpting of tumour cells by the immune
system [89].
One of the best described functions of STAT1 in cancer immu-
noediting is the regulation of innate and adaptive immune
responses against transformed cells. Stat1-deficient natural killer
(NK) cells showed impaired cytotoxic activity against a number
of different target cells in vitro [90–92]. Accordingly, Stat1-/- mice
had a dramatically reduced ability to reject adoptively trans-
planted NK cell-targeted tumour cells [91,92]. Comparative studies
of Stat1-/- mice with mice that lack a functional type I IFN receptor
(Ifnar1-/-), a functional IFNc receptor (Ifngr1-/-) or both receptors,
indicate that STAT1 facilitates NK cell cytotoxicity in a type I and
type II IFN-dependent but also in an IFN-independent manner
[91]. It is still unclear how exactly STAT1 drives NK cell cytotoxic-
ity, but STAT1 is not required for the expression of granzymes andPlease cite this article in press as: K. Meissl et al., The good and the bad face
cyto.2015.11.011perforin [91,92]. Interestingly, STAT1 serine 727 phophorylation
negatively regulates NK cell cytotoxicty as evidenced by an
increased target cell killing and tumour growth control by NK cells
from mice that harbour a point mutation in the Stat1 gene
(Stat1S727A) [92]. Functional defects of Stat1-/- NK cells may in part
reflect impaired splenic NK cell maturation [92,93], although this
remains to be experimentally tested. NK cell maturation is regu-
lated by STAT1-dependent, cell-extrinsic mechanisms as Stat1-/-
NK cells mature comparably to wild-type NK cells in a STAT1-
proficient environment [93]. A similar phenotype was observed
in splenic NK cells from Ifnar1-/- mice and, less pronounced, in
Tyk2-/- mice, but not in mice that lack IFNc [94–96], suggesting that
these functions of STAT1 are mediated through type I IFN
signalling.
Similar to NK cells, Stat1-/- T cells showed impaired cytotoxicity
and failed to reject T cell-controlled tumour cells. Lack of lytic
activity in Stat1-/- T cells correlated with reduced serine esterase
activity and an impaired production of IFNc [90]. Cell-extrinsic
functions of STAT1 likely contribute to the anti-tumour T cell activ-
ity. Type I IFNs, for example, promote the cross-presenting ability
of CD8a+ dendritic cells (DCs) to CD8+ T cells, which is required
for CD8+ T cell priming and tumour rejection and depends on
STAT1 [97,98].
In addition to its crucial role in immune cells, STAT1 regulates
surface receptor expression on tumour cells that affect their
immunogenicity and recognition by immune cells. For example,
major histocompatibility complex class I (MHC class I) molecules,
which present antigens to cytotoxic T cells, are long-known IFN/
STAT1 target genes [99,100]. In addition, some cell types (e.g. B
cells) rely on activated STAT1, but not IFNs, for the basal expression
of MHC class I [100]. STAT1-dependent up-regulation of MHC class
I is required for an effective recognition and elimination of MCA-
induced tumours by cytotoxic T cells [42,101]. In line with the find-
ings in mice, down-regulation of human leukocyte antigen class I
levels (HLA, the human equivalent of MHC class I) through the
up-regulation of SHP2, a negative regulator of STAT1, was
described as an escape mechanism from cytotoxic T cell-
mediated killing in human head and neck cancer cells [102].
2.3. Suppression of angiogenesis
Tumours are highly dependent on oxygen and nutrition supply
by newly formed vessels. Vessel formation is determined by
endothelial cell proliferation and migration as well as the balance
of pro-angiogenic and angiostatic factors [103,104]. Anti-
angiogenic functions of STAT1 have been demonstrated in several
experimental models. Stat1-/- mice showed increased vascular den-
sity in an in vivo angiogenesis assay using matrigel supplemented
with vascular endothelial growth factor (VEGF) and fibroblast
growth factor (FGF) [105]. Activation of STAT1 by IFNc inhibited
cell growth and differentiation of human endothelial cells [105]
and activation of STAT1 by IL-27 inhibited human endothelial cell
proliferation and induced the angiostatic chemokines CXCL10 and
CXCL11 [106]. A pro-apoptotic effect of STAT1 was recently also
described in vessel pruning, a process that involves clearance of
endothelial cells. pSTAT1 activated transcription of c-Jun N-
terminal kinase 3 (Jnk3) and induced cell death [107]. In line with
these findings, formation of vessels within tumour tissue is sup-
pressed by STAT1. Stat1-/- tumour cells displayed enhanced tumour
growth and tumour angiogenesis when xenotransplanted into
nude mice [108]. Re-expression of STAT1 reversed the phenotype
alongside with a lower production of pro-angiogenic molecules,
such as VEGF, basic FGF (bFGF), matrix metalloproteinase
(MMP)-2 and MMP-9 [108]. Similar to endothelial cells, IL-27/
STAT1 inhibits the production and secretion of pro-angiogenic fac-
tors in non-small cell lung cancer cells [109]. Moreover, activateds of STAT1 in solid tumours, Cytokine (2015), http://dx.doi.org/10.1016/j.
Fig. 2. Tumour promoting functions of STAT1. STAT1 activation and enhanced
expression in tumour cells is induced by different stimuli including known
activators (IFN), action of oncogenes or loss of tumour suppressors, interaction
with the tumour stroma or by genotoxic agents (black arrows). The consequences of
STAT1 actions in tumour cells are manifold and include the generation of an
immunosuppressive tumour microenvironment (purple arrows) and the alteration
of cellular processes/pathways (orange arrow). Tumours with high STAT1 levels,
express an IRDS, which is linked to therapy resistance. Translation, autophagy and
apoptosis in tumour cells are also changed by STAT1 and may contribute to therapy
resistance. Furthermore, STAT1 enhances invasion and metastasis of tumour cells.
K. Meissl et al. / Cytokine xxx (2015) xxx–xxx 5STAT1 induced the expression of CXCL10 and CXCL11 in prostate
cancer cells [110] and repressed the transcriptional activity of
hypoxia-inducible factor a (HIF1a), which induces pro-
angiogenic molecules, in glioblastoma cell lines [111].
3. Tumour promoting functions of STAT1
Partially conflicting with the data from human breast cancer
specimens presented in chapter 2, a correlation of STAT1 protein
expression or pSTAT1 levels with poor prognosis has been reported
in three studies. Already in 1995, elevated activation of the STAT
family members STAT1, STAT3 and STAT5 was reported in breast
carcinoma compared to normal, non lactating mammary glands
[112]. High levels of pSTAT1 were detected in aggressive invasive
breast cancer compared to non-invasive ductal carcinoma in situ
[113]. High Stat1 mRNA correlated with poor disease outcome,
whereas high levels of pSTAT1 favoured good prognosis [33]. In
addition, high protein expression of STAT1 together with high
levels of CD74 defined a subtype of triple negative breast cancer
(TNBC) with increased invasive and metastatic potential [114]. In
soft tissue sarcoma, high levels of cytoplasmic U-STAT1 in tumour
cells correlated with bad prognosis and metastasis, whereas high
nuclear pSTAT1 levels were linked to longer survival time [115].
STAT1 promotes tumour growth by diverse processes that range
from an evasion from and suppression of tumour immune surveil-
lance and an increase in invasiveness/metastasis to the acquisition
of resistance against irradiation and chemotherapy (Fig. 2).
3.1. Promotion of tumour cell growth and invasiveness
In esophageal tumours STAT1 supports invasion of tumour cells
harbouring mutated p53 and expressing periostin, an integrin
ligand, in in vitro invasion assays [116]. Depletion of the tumour
suppressor p19ARF in p53-deficient cells, led to an increase in Stat1
expression, enhanced proliferation in vitro and increased tumour
formation in nude mice. IFNb treatment of p53-deficient cells phe-
nocopied the loss p19ARF protein, indicating that IFNb is sufficient
to promote cell growth. IFN-induced 15 kDa protein (ISG15), a
STAT1 target gene, appears to be the major driver of cell prolifera-
tion in this cell system, as knock-down of Isg15 reduced cell growth
in soft agar, foci formation and proliferation [117]. In colon cancer
cells, activation of STAT1 by ectopic overexpression of the onco-
gene cancer upregulated gene 2 (CUG2) possibly via the AKT/ERK
pathway enhanced migratory capacity and conferred resistancePlease cite this article in press as: K. Meissl et al., The good and the bad face
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linked to transformation by the oncoprotein mucin 1 (MUC1).
MUC1 is frequently overexpressed in human breast cancers and
is proteolytically cleaved into two subunits. STAT1 constitutively
interacts with the MUC1-C subunit in breast cancer cells which
results in an up-regulation of STAT1 target genes and MUC1 itself.
The importance of this interaction is evidenced by the finding that
activated STAT1 and MUC1 expression correlated with reduced
breast cancer patient survival [119]. The transmembrane protein
MUC4, together with epithelial growth factor receptor (EGFR) fam-
ily members, is critical for invasiveness and metastasis of pancre-
atic cancer. As for MUC1, aberrant MUC4 expression is a
hallmark of epithelial cancers [120]. It exerts its oncogenic activity
mainly through the EGFR family member HER2. MUC4 expression
is crucially regulated by IFNc/STAT1 and cross-talks to other sig-
nalling pathways [121,122]. Recently it was shown, that therapeu-
tic targeting of EGFRs leads to reduced pSTAT1 and MUC4 levels in
pancreatic cancer cells, which reduced tumour growth and metas-
tasis [123].
In contrast to the pro-apoptotic function of pSTAT1, a recent
study provided convincing evidence that U-STAT1 acts anti-
apoptotic. Silencing of STAT1 in soft tissue sarcoma cells, which
express high levels of U-STAT1 and low levels of pSTAT1, resulted
in increased expression of the pro-apoptotic proteins FAS and Bcl-
2-associated agonist of cell death (BAD) and in increased FAS-
mediated apoptosis. Furthermore, high U-STAT1 levels in human
soft tissue sarcomas correlated with a reduction in survival,
whereas high pSTAT1 levels in tumour cells correlated with an
increased survival [115].
3.2. Immune evasion and suppression
STAT1 promotes tumour growth by inducing an immunosup-
pressive tumour environment. In invasive breast carcinoma tissue
with high STAT1 activity, infiltration of myeloid derived suppressor
cells (MDSCs) was enhanced compared to ductal carcinomas [113].
Ectopic overexpression of constitutively active STAT1 prompted
mobilisation of MDSCs and resulted in a more aggressive tumour
growth upon transplantation into immunocompetent mice. These
tumours expressed high levels of pro-inflammatory TNFa and
immunosuppressive cytokines (e.g. TGFb1 and IL-13). Gene
knock-down of Stat1 reversed these events and attenuated tumour
progression [113]. In a cohort of breast cancer specimen, elevated
STAT1 expression levels in the tumour cells were associated with
the infiltration of tumour-associated macrophages (TAMs) [33].
Evidence for a cell-intrinsic function of STAT1 in regulating TAM
activity was provided by the findings that STAT1 activation is nec-
essary for the suppressive function of TAMs on T cell responses
[124] and that STAT1 levels in TAMs correlate with reduced sur-
vival in follicular lymphoma patients [125].
Several lines of evidence from studies in mice and humans, sug-
gest that tumour cell-intrinsic functions of STAT1 also negatively
impact on tumour immune surveillance. STAT1 induced the
expression of the immune checkpoint protein PD-L1 (B7-H1) upon
IFNc stimulation in non-transformed and tumour cells [126–128].
Furthermore, STAT1 gain-of-function mutations in humans, are
associated with increased PD-L1 surface expression on naïve
CD4+ T cells [129]. IFNc/STAT1-induced PD-L1 expression on
tumour cells inhibits T cell and NK cell functions as assessed by
in vitro target cell killing assays [126,127].
Although the aformentioned up-regulation of MHC class I mole-
cules on tumour cells is needed for the anti-tumour activity of T
cells, it goes along with an escape from NK cell recognition. In
the case of a hematopoietic tumour that is immunologically con-
trolled mainly by NK cells, loss of STAT1 and MHC class I rendered
these cells better NK cell targets and delayed disease progressions of STAT1 in solid tumours, Cytokine (2015), http://dx.doi.org/10.1016/j.
6 K. Meissl et al. / Cytokine xxx (2015) xxx–xxx[130]. In the case of MCA-induced tumours, loss of STAT1 switches
tumour growth control from T cell- to mainly NK cell-mediated
[131].3.3. Induction of therapy resistance
Tumour therapy involves radiation and chemotherapy.
Acquired therapy resistance is characteristic for late stage cancer
and metastasis and is mainly responsible for therapy failure.
Although STAT1 generally acts pro-apoptotic and potentiates
effects of genotoxic agents, there is increasing evidence that high
STAT1 expression and/or activation confers therapy resistance.
Activation of STAT1 signalling and the acquisition of a radioresis-
tant phenotype of cancer cells after serial transplantations in com-
bination with irradiation was reported in squamous cell carcinoma
cells. Gene expression profiling of these resistant cells revealed a
pre-dominant expression of IFN-stimulated genes (ISGs) and was
termed IFN-related DNA damage resistance signature (IRDS)
[132]. The induction of the IRDS after irradiation was later also
detected in xenografts from different tumour cell lines, including
breast cancer, head and neck cancer, colon cancer, prostate carci-
noma and gliosarcoma [133,134]. Moreover, an IRDS correlates
with poor prognosis in breast cancer, head and neck cancer, lung
cancer, prostate cancer and glioblastomas [135,136]. The possible
underlying mechanisms for the induction of an IRDS include sus-
tained exposure to IFNs (from tumour stroma), irradiation, or the
selection of a resistant subclone in the heterogenous tumour tissue
[137]. Type I IFN (and possibly type III IFN) production may be
induced by recognition of danger-associated molecular patterns
(DAMPs) released from dying cells. Interestingly, a recent study
demonstrated that exosomes secreted by stromal cells that contain
non-coding RNA, activate retinoic acid-inducible gene 1 (RIG-1), a
member of the pattern recognition receptors (PRRs), in breast can-
cer cells. RIG-1 activates type I IFN production and subsequent
pSTAT1-driven ISGs expression. Simultaneously, stromal cells acti-
vate NOTCH3 signalling in breast cancer cells. This co-activation
mediates resistance of breast cancer cells and leads to the out-
growth of a resistant subclone [138].
Several additional mechanisms may lead to an up-regulation of
STAT1 expression and/or activity in tumour cells. Cisplatin-
resistant ovarian cancer cells showed sustained pSTAT1 mediated
by histone deacetylase 4 (HDAC4) [139]. Up-regulation of STAT1
and ISGs can also occur through a concomitant loss of p53 and
p19ARF as demonstrated in MEFs. A subset of TNBC patients har-
bours coinactivation of p53 and p14ARF (the homolog of mouse
p19ARF) together with an overexpression of STAT1, indicating that
these findings are relevant for human cancers [117].
The mechanisms by which STAT1 induces therapy resistance
likely depend on the context and occur at multiple levels. A
transcriptome-proteome approach with squamous cell carcinoma
cells indicates that STAT1 blocks an irradiation-induced downreg-
ulation of metabolic pathways. Radio-sensitive STAT1 knock-down
cells showed reduced expression of genes linked to metabolic
pathways (e.g. glycolysis/glyconeogenesis, citrate cycle and oxida-
tive phosphorylation) compared to their radio-sensitive wild-type
counterparts. Although the effects of STAT1 on particular meta-
bolic pathways needs further investigation, this report raises the
possibility that STAT1 is involved in the regulation of the Warburg
effect [140], i.e. the tumour cells’ switch from oxidative phospho-
rylation to anaerobic glycolysis [141]. Its regulation is under inten-
sive investigation and recent findings suggest that it is modulated
by several oncogenes and tumour suppressors [142].
In human lung cancer cells resistance to the topoisomerase
inhibitor etoposide is mediated by a STAT1-dependent up-
regulation of HDAC4 and multidrug resistance (MDR) 1 gene [143].Please cite this article in press as: K. Meissl et al., The good and the bad face
cyto.2015.11.011While IFNc-induced autophagy contributes to cell death and
acts anti-tumourigenic, type I IFN-induced autophagy counteracts
their pro-apoptotic function and might contribute to therapy resis-
tance. This phenomenon has been shown for IFNb treated human
breast cancer cells and human glioma cells, and for IFNa treated
human myeloid leukaemia cells [144–146]. In breast cancer and
myeloid leukaemia cells, induction of autophagy by type I IFNs is
STAT1 dependent. In glioblastoma, induction of autophagy by an
angiogenesis inhibitor is governed by IRF1, a STAT1 target gene
product, and counteracts apoptosis and leads to therapy resistance
[147].
Recently, selective translation of specific mRNAs in parallel with
reduced general translation has been proposed as a mechanism for
the induction of therapy resistance by STAT1. Most of the nuclear
eukaryotic genes have a cap-structure at their 50 end which is rec-
ognized by the translation machinery. STAT1 stimulates cap-
independent translation of a subgroup of mRNAs with an internal
ribosomal entry site (IRES), such as p27KIP1, Bcl-xL and X-linked
inhibitor of apoptosis protein (XIAP). This translational switch is
mediated by a STAT1-dependent proteasomal degradation of pro-
grammed cell death 4 (PDCD4). Degradation is induced by a
PI3K-mediated activation of Akt and S6K and the phosphorylation
of PDCD4. STAT1 increased viability of immortalized MEFs treated
with either PI3K/mTOR inhibitors or the cytostatic drug doxiru-
bicin, indicating that the translational switch impacts on cell sur-
vival and may contribute to chemoresistance conferred by STAT1
[148].
Overexpression of STAT1 not only confers resistance to irradia-
tion, but also impairs apoptosis induced by IFNc, TNFa, TRAIL and
FAS, through the production of IL-6 and IL-8 ([149] and see above).4. Summary and outlook
The role of STAT1 in tumourigenesis is complex, as its functions
are not restricted to tumour cells, but extend to different compart-
ments of the tumour microenvironment (e.g. immune cells,
endothelial cells). Although STAT1 abundance is a reliable marker
for good prognosis in selected tumour types, it can also correlate
with disease progression. Divergent findings can be due to differ-
ences in tumour type and/or stage but may also reflect tumour
heterogeneity. More detailed mechanistic analysis of the tumour
cell-intrinsic and extrinsic functions of STAT1 and their contribu-
tion to carcinogenesis will help to fully exploit the diagnostic
and therapeutic potential of STAT1. An intriguing facet of STAT1
function is its interconnection with other STATs. The most promi-
nent example is STAT3, which can either positively or negatively
influence STAT1 function [150,151]. The association of high STAT1
expression and/or activity with therapy resistant tumour types
suggests that selective STAT1 inhibitors may be useful in cancer
therapy. Selective inhibitors for STAT3 and STAT5 are rapidly
advancing [152] and STAT1 inhibitors are within reach [153]. Inhi-
bitors will help to shed light on the multifaceted functions of
STAT1 in tumourigenesis and might open future paths in cancer
therapy.
The concept of cancer immunotherapy, often in combination
with oncogene inhibitors or classical chemo-/radiotherapy, is cur-
rently tested in clinical settings and promises to achieve long-
lasting remission or eradication of tumours. In this context, type
I and II IFNs currently experience a revival [154,155] with type
III IFNs and interleukins IL-21, IL-27 and IL-35 joining the list of
promising anti-tumour agents [156–159]. Controlled STAT1 func-
tion is a prerequisite for, or at least significantly contributes to,
arming the immune system against tumour cells through these
cytokines.s of STAT1 in solid tumours, Cytokine (2015), http://dx.doi.org/10.1016/j.
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